SoftBank Leads $80 Million Round in Digital Health Startup
- Pear has FDA-approved prescription digital therapies
- The round is joined by existing investors including Temasek
This article is for subscribers only.
SoftBank Group Corp.’s Vision Fund 2 led an $80 million investment in Pear Therapeutics Inc., a startup developing prescription software applications aimed at treating substance use disorders, schizophrenia and multiple sclerosis.
Existing investors Temasek Holdings Pte, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, Novartis AG, CrimsoNox and EDBI also joined the Series D round, the Boston, Massachusetts-based startup said in a statement. Forth Management, Pilot House, Sarissa Capital, Shanda Group Pte, and Quad Investment Management took part as first-time investors in the company.